Spanish Research at ESMO 2014

It is has been ESMO’s pleasure to work closely with SEOM, the Spanish Society of Medical Oncology, leading up to the ESMO 2014 Congress. ESMO has benefited from the knowledge of the local oncology community and we thank SEOM for welcoming ESMO to beautiful, historic Madrid

We are thankful for the important contribution of Spanish oncologists to the ESMO 2014 scientific programme. We highlight here some of the original, local research which will be presented during the congress. 

ESMO-SEOM Joint Symposium 

Moderators: R.A. Stahel (Zürich/CH), P. Garrido Lopez (Madrid/ES)
Session Info:  Joint Symposium, [] ESMO-SEOM Joint Symposium 
Date/Time: Monday 29 September 2014 / 2:15 PM-3:45 PM
Room: Granada

Proferred Papers

Gastrointestinal tumours, colorectal

Date/Time: Saturday 27 September 2014 / 8:45 AM-10:45 AM
Room: Madrid

499O | Phase II study of first-line mFOLFOX plus cetuximab (C) for 8 cycles followed by mFOLFOX plus C or single agent (s/a) C as maintenance therapy in patients (p) with metastatic colorectal cancer (mCRC): the MACRO-2 trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]) 

CNS tumours

Date/Time: Saturday 27 September / 2:00 PM-3:45 PM
Room: Salamanca

417O | MGMT methylation in tissue and serum from unresectable glioblastoma (GBM) patients (p) included in the GENOM 009 Study, a multicenter randomized study by the GEINO Group comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV). (ClinicalTrials.gov NCT01102595)

Public health and health economics

Date/Time: Sunday 28 September 2014 / 3:45 PM-5:30 PM
Room: Pamplona

1385O | Author Financial Conflicts of Interest (FCOIs) in Clinical Practice Guidelines (CPGs) for Systemic Anti-cancer Drugs

SCLC and other thoracic malignancies

Date/Time: Monday 29 September 29, 2014 / 2:00 PM-3:30 PM
Room: Sevilla

1556O | Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Poster Discussion

NSCLC early stage, SCLC and other thoracic malignancies 

Date/Time: Saturday 27 September 2014 / 12:45 PM-1:45 PM
Room: Cordoba

1179PD | Prognostic impact of immune microenvironment markers in tumor and stroma in resectable NSCLC

Gastrointestinal tumours, colorectal

Date/Time: Saturday 27 September 2014 / 1:00 PM-2:00 PM
Room: Granada

507PD | POSEIDON Phase I/II trial: abituzumab combined with cetuximab plus irinotecan as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer

Sarcoma

Date/Time: Saturday 27 September 2014 / 1:00 PM-2:00 PM
Room: Valencia

1416PD | Integrating genotype in risk classification for GIST recurrence. A Spanish Group for Sarcoma Research (GEIS) study

Metastastic and locally advanced breast cancer: Facing with heterogeneity and endpoints in clinical trials

Date/Time: Sunday 28 September 2014 / 12:45 PM-1:45 PM
Room: Cordoba

358PD | Vinflunine (VFL) plus capecitabine (CAPE) for advanced breast cancer (ABC) previously treated with or resistant to anthracycline and resistant to taxane : a phase 3 study versus capecitabine

Gastrointestinal tumours, non-colorectal

Date/Time: Sunday 28 September 2014 / 12:45 PM-1:45 PM
Room: Pamplona

616PD | A ph 1b study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer

Head and neck cancer

Date/Time: Sunday 28 September 2014 / 1:00 PM-2:00 PM
Room: Bilbao

992PD | Residual neck disease (RND) management in squamous-cell carcinoma of the head and neck (SCCHN) treated with radiotherapy (RT) plus cetuximab (C)

Neuroendocrine & endocrine tumours and CUP

Date/Time: Monday 29 September 2014 / 12:45 PM-1:45 PM
Room: Alicante

1140PD | Finding molecular subgroups of worse prognosis studying the microenvironment of gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)

NSCLC, metastatic

Date/Time: Monday 29 September 2014 / 1:00 PM-2:00 PM
Room: Granada

1230PD | Phase 1b study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with carboplatin (Carbo)/paclitaxel (Pac) ± bevacizumab (Bev) and cisplatin (Cis)/pemetrexed (Pem) in patients (pts) with advanced solid tumors and NSCLC

Supportive and palliative care

Date/Time: Monday 29 September 2014 / 1:00 PM- 2:00 PM
Room: Bilbao

1485PD | Outpatient management of cancer-related pulmonary embolism: a propensity score-matched analysis of 803 patients from the EPIPHANY study

1486PD | Prognostic evaluation of clinically stable febrile neutropenia: prospective data from 921 patients from the FINITE study 

Poster Display Sessions 1

Date/Time: Saturday 27 September 2014 / 12:45 PM-1:45 PM
Room: Poster Area

View Poster Display Sessions

Breast cancer, locally advanced

339P | A Prognostic Index for Locoregional Recurrence (LRR) after Neoadjuvant Chemotherapy (NAC)

341P | Title: Accuracy of magnetic resonance imaging prediction of pathologic complete response in patients with breast cancer treated with neoadjuvant chemotherapy

346P | Concordance between radiological and pathological response in axillary lymph nodes in patients with breast cancer treated with neoadjuvant chemotherapy

Breast cancer, metastatic

362P | Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625

370P | Mean overall survival (OS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoparticle albumin-bound paclitaxel (nab-P) vs conventional solvent-based paclitaxel (sb-P) in metastatic breast cancer

407P | PIK3CA mutations and loss of PTEN expression in Circulating Tumor Cells (CTCs) in patients with Metastatic Breast Cancer (MBC)

409TiP | Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

411TiP | A phase I study of LDE225 in combination with docetaxel in patients with Triple Negative (TN) Advanced Breast Cancer (ABC): GEICAM/2012-12

Developmental therapeutics

482P | Lurbinectedin (PM01183) on Days (D) 1 & 8 in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer

488P | Implementation of a pharmaceutical care programme for patients treated with investigational oral drugs in a clinical trials unit

Familial cancer

496P | A multidisciplinary approach to heredofamilial cancer syndromes: evaluation of the first four years of experience at a Spanish University Hospital 

Genitourinary tumours, prostate

779P | MicroRNAs expression in blood associated with taxanes response and overall survival in metastatic castration-resistant prostate cancer

781P | Analysis of European patients enrolled in a global early access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer progressing after chemotherapy

783P | Preliminary results of a phase II study of weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel treatment (SOGUG-CABASEM trial)

784P | Pharmacokinetic (PK) activity of cabazitaxel (Cbz) in patients (pts) with renal impairment (RI)

Genitourinary tumours, non-prostate

829P | Early-onset hypothyroidism and survival in patients with advanced renal cell carcinoma treated with first-line sunitinib: updated overall survival data

842P | Clinical outcomes in patients (p) with metastatic renal cell carcinoma (mRCC) receiving several lines of target therapy: retrospective analyses of a cohort of three multidisciplinary centres from Spain 

849P | Real life efficacy and safety of axitinib (AXI) in patients with renal cell carcinoma (RCC): Results from the Spanish compassionate use program 

852P | Can radiological parameters predict the outcome in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib? Usefulness of normalized arterial density and blood flow

869P | Pharmacogenetic study of cabazitaxel in advanced or metastatic transitional cell carcinoma (TCC): The SOGUG 2011-04 trial 

871P | Incidence and pattern of Second Neoplasms in Patients diagnosed with invasive transitional Carcinoma of the Urinary tract

Gynaecological cancers

889P | Phase I dose-escalation study to determine the maximum tolerated dose (MTD) of nintedanib (BIBF 1120) in combination with carboplatin/pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent ovarian cancer (ROC)

907P | Association between angiogenesis-related genes and the response to multimodal therapy in high-grade serous Advanced Ovarian Carcinoma (AOC)

926P | Impact of demographic characteristics, staging methods and treatment in a European Locally advanced Cervical Cancer (LACC) population

Neuroendocrine & endocrine tumours and CUP

1147P | Everolimus (EVE) treatment for advanced G1-G2 neuroendocrine tumours (NETs) in the community setting: clinical benefit irrespective of grade or primary tumour site

1161P | Safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive Medullary Thyroid Cancer (MTC) 

NSCLC, locally advanced

1202P | Pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation after Pem+Cis induction in patients (pts) with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC): results in different age groups (≤70 yrs, >70 yrs)

1220TiP | Multi-arm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling

NSCLC, metastatic

1248P | A phase Ib open label clinical trial of continuous once daily oral afatinib (A) plus sirolimus (S) in patients (pts) with EGFR mutation positive (EGFR M+) NSCLC and/or disease progression following prior erlotinib (E) or gefitinib (G)

1295P | Efficacy and Safety of Ceritinib in Patients (pts) with Advanced Anaplastic Lymphoma Kinase (ALK)-rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

1336TiP | Phase (Ph) 3 study of patritumab (P) plus erlotinib (E) in EGFR wild-type subjects with advanced non–small cell lung cancer (NSCLC) 

Poster Display Sessions 2

Date/Time: Sunday 28 September 28 / 12:45 PM-1:45 PM
Room: Poster area

View Poster Display Sessions

Biomarkers

170P | Modification of methylation level DNA promoter in serum of a panel of gene before and after treatment and impact in prognostic factor in patients with breast cancer

172P | Triple negative breast cancer: clinicopathologic characteristics and Fatty Acid Synthase (FASN) expression as a potential target

182P | Targeting the expression of the Inhibitor of Differentiation (Id) genes in tumor microenvironment (TME) and tumor cells is crucial in the prevention of liver metastasis (LM) from lung cancer 

186P | PALB2 mRNA Expression as a Predictive and Prognostic Marker in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) Treated with Cisplatin- Docetaxel Chemotherapy 

193P | Heterogeneity of met assessed by immunohistochemistry (IHC) and fluorescence-in-situ hybridization (FISH) in nonsquamous non-small cell lung cancer (nsNSCLC) 

227P | Prognosis of phosphorylated-Insulin Growth factor receptor (p-IGF-1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST) patients treated with imatinib. A GEIS study 

248P | Monitoring circulating tumor cells (CTC) in lung cancer: Preliminary results 

252P | Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins 

CNS tumours

421P | Cross-talk between the Notch and Transforming Growth Factor-β (TGF-β) signaling pathways in Glioma initiating cells (GICs)

424P | Patient profile and therapeutic management in Glioblastoma (GBM): A subgroup analysis of a large prospective observational study of the Neuro-Oncology Investigation Spanish Group (GEINO)

426P | Glioblastoma in elderly patients: survival outcome

430P | GEINOFOTE: safety and activity analysis of the use of fotemustine (FT) in different schedules in progressive glioblastoma (GB) in Spain

434P | Rechallenge with bevacizumab (BEV) in patients (p) with glioblastoma (GBM) and previous objective response to BEV

Haematological malignancies

953P | Lenalidomide plus metronomic cyclophosphamide for heavely pretreated classical Hodgkin Lymphoma. A phase II trial

958P | Does the presence of hepatitis virus B & C influence the evolution of Diffuse Large B-cell Lymphomas?

968P | Real world experience with temsirolimus in patients with relapsed or refractory mantle cell lymphoma: Results from the Spanish experience

Melanoma and other skin tumours

1108P | BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: preliminary results from the Spanish Melanoma Group prospective study GEM1304

1123P | Treatment patterns of Adjuvant Interferon alfa-2b (IFN-α2b) for High-risk Melanoma. A retrospective study of the Grupo Español Multidisciplinar de Melanoma (GEM)

Prevention and screening

1362P | Using an informed consent in mammography screening: Final result of a randomized trial

1364P | Spanish women’s perceptions of mammography screening

Supportive care

1504P | Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE study

1506P | Analysis of clinical factors for ambulatory management in patients with febrile neutropenia

Poster Display Sessions 3

Date/Time: Monday 29 September 2014 / 12:45 PM-1:45 PM
Room: Poster area

View Poster Display Sessions

Breast cancer, early stage

270P | Prognostic value of Residual Disease in Breast and Nodes (RDBN), a histopathologic system to evaluate the response after neoadjuvant chemotherapy (NAC) in breast cancer

282P | Prospective evaluation of two multi-gene assays in node-negative, estrogen receptor-positive (ER+) breast cancer patients to aid adjuvant clinical decision making in a community-based study

295P | Traditional prognostic factors used for adjuvant chemotherapy (CT) decisions in early stage HR+, HER2– breast cancer in a large international survey (MAGIC) among breast cancer specialists 

Gastrointestinal tumours, colorectal

530P | Angiogenic Switch as Predictor of Response to Chemotherapy+ Bevacizumab in Patients with Metastatic Colorectal Cancer

551P | RAS analysis of the PLANET study: Phase II trial of panitumumab (P) plus FOLFOX4 or FOLFIRI in subjects with wild-type (WT) KRAS colorectal cancer (CRC) and liver-limited disease (LLD)

555P | Association between colon cancer molecular subtypes obtained by expression profiling and by microRNA (miR) profiling

567P | Role of circulating tumor cells (CTC) in stage III colorectal cancer (CRC)

594P | Peritoneal Carcinomatosis (PC) from Colo-Rectal origin. Results of 200 patients treated by Radical Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Catalonian Peritoneal Carcinomatosis Program (Spain)

599P | A validation of current prognostic scores in metastatic colorectal cancer (mCRC) and a new prognostic score (A GEMCAD study)

603P | Improving clinical outcomes in cancer care through centralisation of treatment and clinical audit: the rectal cancer case

Gastrointestinal tumours, non-colorectal

628P | A meta-analysis on the efficacy of second line (2L) treatment options for advanced gastric cancer (AGC)

634P | Prognostic evaluation of a multicenter cohort of 484 patients with metastatic gastroesophageal adenocarcinoma

644P | Induction chemotherapy followed by chemoradiotherapy in locally advanced esophagogastric adenocarcinoma. Has the location of the primary tumor any influence on patients’ outcome? A retrospective analysis

645P | Induction chemotherapy, chemo-radiotherapy and surgery in locally advanced gastric cancer (GC) patients: long term results from a single institution

667P | Altered expression of cMET and PIK3CA are associated with primary gastric cancer

675P | Peritoneal carcinomatosis (PC) from gastric origin. 26 consecutive patients treated by radical surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Results from the Catalonian Peritoneal Carcinomatosis Programme (Spain)

677P | Consecutive complete radical surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in patients with peritoneal carcinomatosis (PC). Clinical results and survival according to malignancy type (Spain)

700P | A phase (Ph) I/II trial to evaluate the efficacy (E) and safety (S) of nab-paclitaxel (nab-P) in combination (Co) with gemcitabine (G) for the treatment (Tr) of frail (Fr) patients (P) with advanced or metastatic pancreatic cancer (aPC): Safety results of the Phase I trial

705P | Premature mortality in pancreatic cancer: Analysis of lost life-years and quality-adjusted life-years (QALYs) in Europe

712P | A three-step strategy of induction chemotherapy, chemo-radiotherapy and surgery in locally advanced pancreatic cancer (LAPC) patients. Role of a nonlinear mixed effects modeling to predict outcome

Head and neck cancer

1002P | HEAD AND NECK CANCER IN THE ELDERLY: Is there any reason to change their management?

1007P | Cetuximab and Concurrent Radiation (CTX-RT) for Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Elderly and Multi-morbid Patients

1032P | Prolonged anti-tumor activity of Lucitanib in advanced Thyroid Cancer

1035TiP | Induction chemotherapy (ICT) with docetaxel/cisplatin/5-fluorouracil (T/P/F) followed by chemoradiotherapy with Cisplatin (CRTP) vs bioradiotherapy with Cetuximab (RTCx) for unresectable locally advanced head & neck cancer (ULAHNC): Preliminary results on toxicity a TTCC Group Trial 

Immunotherapy of cancer

1064P | A Phase 1 study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously - Analysis of dose expansion and repeat cycle cohorts in patients with metastatic colorectal cancer (mCRC)

1067P | Pathological complete response and changes related to T infiltrating lymphocytes and regulatory T cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinoma

1068P | A phase 1 mechanism of action study of intra-tumoural (IT) or intravenous (IV) administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumour

1076TiP | Randomized phase II trial with dendritic cell (DC) immunotherapy in patients with colorectal carcinoma and liver metastasis following complete resection and adjuvant chemotherapy

1078TiP | Phase II study with immunotherapy with dendritic cells (DC) combined with intratumoral hiltonol in patients with advanced cancer

NSCLC, early stage

1189P | Prognostic impact of VEGFA in resectable Non-Small-Cell Lung Cancer 

Public health

1394P | Breast cancer fast-track programme to shorten time between initial symptoms, diagnosis and initiation of treatment

1405P | A prognostic model of survival after first hospital discharge of cancer patients

Sarcoma

1432P | Second primary malignances (SPMs) in patients (p) with gastrointestinal stromal tumors (GISTs) – a coincidence or an effect of imatinib?

1449P | Results of clinical audit on the quality of sarcoma management support centralisation of rare cancer care in Catalonia (Spain)

1452P | Multidisciplinary treatment outcome of desmoid-type fibromatosis (DTF). A registry-based study from Spanish Group for Research on Sarcoma (GEIS) 

1453P | Solitary Fibrous Tumor (SFT): A Registry Program to assess frequency and managemente in our country. A Spanish Group for Research on Sarcoma (GEIS) Study

Thoracic malignancies, other

1568P | Thoracic Malignancies And Other Second Neoplasms In Hodgkin Lymphoma Survivors

Translational research

1576P | Genome wide association study (GWAS) for identification of single nucleotide polymorphisms (SNPs) associated with individuals presenting extreme phenotypes of tobacco induced non-small cell lung cancer (NSCLC) risk

1600P | Phospho-kinase expression and anti-tumoral activity of the novel multikinase inhibitor EC-70124 in colon cancer

1619P | Mutational analysis of circulating DNA and cells in patients with metastatic colorectal cancer

1624P | Molecular prescreening vs. unselected clinical trials for cancer patients in a tertiary oncology department

Tumour biology and pathology

1630P | Genomic characterization of early stages of ovarian cancer with emphasis in low-grade endometroid and low-grade serous histologies. A study by Spanish Group for Ovarian Cancer Research (GEICO)

1634P | Inhibitor of differentiation-1 (Id1) and Id3 expression correlates with Epithelial-Mesenchymal Transition (EMT)-related proteins (EMTrp) in Non-Small Cell Lung Carcinoma (NSCLC)

1635P | Comparison of the 2007 and 2013 ASCO/CAP guidelines for HER2 ISH testing in invasive breast cancer patients

1636P | ROS1 rearrangements and copy number alterations in NSCLC patients: High frequency of ROS1 deletions